Drugs / SARS-CoV-2 Bivalent mRNA Vaccine
SARS-CoV-2 Bivalent mRNA Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05939648 | Oct → Nov 2023 | COVID-19 | AIM Vaccine Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 Bivalent mRNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05939648 ↗ |
| Modality | Messenger RNA (mRNA) | “SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)” NCT05939648 ↗ |